CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China

TIANJIN, China, Jan. 8, 2022 /PRNewswire/ — CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China (“NMPA”) granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) (“MCV4”, trade name:…